Accuray Continues to Set the Industry Standard for Customer Satisfaction

SUNNYVALE, Calif., Jan. 19, 2017 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today that its CyberKnife® and TomoTherapy® Systems continue to set the bar for excellence in customer satisfaction. The Accuray systems received the highest composite overall user satisfaction rating among radiation treatment delivery systems in the U.S., according to the Q4 2016 MD Buyline Market Intelligence Briefing™. The most recent ratings trend also shows Accuray has achieved the highest composite ratings among industry peers for 11 of the past 12 quarters.

According to MD Buyline, the company achieved the highest scores in the majority of categories measured including system performance, system reliability, applications training, service response time and service repair quality. CyberKnife and TomoTherapy System users continue to "praise the high level of reliability afforded by Accuray systems." In addition, CyberKnife System users "highly recommend" the InCise™ Multileaf Collimator mentioning "it makes the treatment time much more efficient." Customer feedback also demonstrates Accuray systems are delivering on radiation therapy department expectations. The system performance ratings have exceeded the industry average for 14 consecutive quarters.

"Our goal is to provide customers with the resources they need to confidently deliver best-in-class radiation treatments for their cancer patients now and in the years to come. Accuray has expanded customer education and training opportunities, and improved service support, as part of our long-term commitment to delivering on this objective," said Joshua H. Levine, president and CEO of Accuray. "The Q4 MD Buyline results reinforce the company's focus and our team's commitment to excellence in meeting customers' needs."

For more information on the CyberKnife and TomoTherapy Systems visit www.accuray.com.

MD Buyline, an independent market intelligence organization for the healthcare industry, measures linear accelerator user satisfaction based on evaluations by more than 3,300 hospitals in its member network that use the product every day. Respondents rate how satisfied they are with products from Accuray, Elekta and Varian, using key metrics listed above along with installation and implementation, applications training, and service repair quality. (MD Buyline User Satisfaction Ratings, MD Buyline Market Intelligence Briefing™ Q4 2016) © 2016 MD Buyline, All Rights Reserved. Used with Permission January 4, 2017.

About the CyberKnife and TomoTherapy Systems
The Accuray CyberKnife M6™ Series and TomoTherapy H™ Series treatment solutions cover the entire spectrum of radiation therapy needs. The CyberKnife M6 Series enables precise, high-quality, high-dose distributions to be confidently delivered to the patient with extreme accuracy over a minimum number of treatments, reducing side effects and preserving patients' quality of life. The CyberKnife® System is the only robotic full-body radiosurgery system available today. The TomoTherapy® H™ Series efficiently enables physicians to customize treatment plans for the entire range of radiation therapy patients and disease types. Its innovative design enables treatment plans to be delivered with integrated, daily CT image guidance, enhancing accuracy and delivering highly precise, intensity-modulated radiation for optimal sparing of healthy tissue and critical structures.

About Accuray
Accuray Incorporated (NASDAQ: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com.

Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 24, 2016, the company's report on Form 10-Q, filed on November 1, 2016, and as updated periodically with the company's other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to Accuray at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

Media Contacts:                                                              
Beth Kaplan                                                                       
Accuray                                                                               
+1 (408) 789-4426                                                            
[email protected]                                 

Sherry Feldberg
MSLGROUP
+1 (781) 684-6223
[email protected]

SOURCE Accuray Incorporated

Related Links

http://www.accuray.com